Converting Insulin Glargine U-100 to Tresiba (Insulin Degludec) FlexTouch U-100
When switching from insulin glargine U-100 to Tresiba (insulin degludec) U-100, start with a unit-to-unit conversion (same total daily dose) in adults, but reduce the dose to 80% of the total daily long-acting insulin dose in pediatric patients (≥1 year old) to minimize hypoglycemia risk 1.
Adult Conversion (Type 1 or Type 2 Diabetes)
- Start Tresiba at the exact same unit dose as your current total daily insulin glargine dose 1
- No dose reduction needed in adults
- Example: If taking 30 units of glargine daily → start 30 units of Tresiba daily
Pediatric Conversion (≥1 Year Old)
- Start Tresiba at 80% of the total daily insulin glargine dose 1
- This dose reduction is critical to prevent hypoglycemia in children
- Example: If taking 20 units of glargine daily → start 16 units of Tresiba daily (20 × 0.8 = 16)
Important Dosing Considerations
Tresiba U-100 FlexTouch pen specifics:
- Delivers doses in 1-unit increments 1
- Maximum single injection: 80 units 1
- No dose conversion calculation needed - the dose window shows actual units to inject 1
- For pediatric patients requiring <5 units daily, use the Tresiba U-100 vial instead of the pen 1
Post-Switch Monitoring and Titration
After switching, implement these critical steps:
- Increase blood glucose monitoring frequency during the transition period 1
- Titrate dose based on fasting plasma glucose (FPG) goals 2
- Use evidence-based titration: increase by 2 units every 3-4 days to reach FPG target without hypoglycemia 2
- For hypoglycemia: identify the cause; if unclear, reduce dose by 10-20% 2
Real-World Evidence on Dose Adjustments
Research data suggests actual dose requirements may differ from the 1:1 conversion:
- One observational study found patients switching from once-daily glargine required approximately 78% of their original basal dose at 6 months (equation: Degludec dose = 3.39 + 0.78 × glargine dose) 3
- Patients on twice-daily basal insulin required approximately 69% of their original total basal dose (equation: Degludec dose = 0.44 + 0.69 × total basal dose) 3
- Total daily insulin doses typically decreased by 17-24% after switching to degludec in real-world studies 4
Critical Safety Points
Common pitfalls to avoid:
- Never transfer Tresiba from the FlexTouch pen into a syringe - this can cause severe dosing errors 1
- Never mix or dilute Tresiba with any other insulin or solution 1
- Never administer intravenously or use in insulin pumps 1
- Always check insulin labels before each injection to prevent medication errors 1
Timing Flexibility
- Adults: Can inject at any time of day (timing can vary day-to-day) 1
- Pediatric patients: Must inject at the same time every day 1
- If a dose is missed in adults: inject during waking hours when discovered, ensuring at least 8 hours between consecutive injections 1
- If a dose is missed in pediatric patients: contact healthcare provider for guidance and increase glucose monitoring 1
Expected Clinical Outcomes
Switching to Tresiba typically results in:
- Improved HbA1c (reductions of 0.19-0.54% observed) 5
- Significantly lower rates of severe and nocturnal hypoglycemia compared to glargine 1, 5
- Reduced glucose variability 4
- Lower total insulin requirements over time 3, 4
The FDA label provides the definitive conversion guidance, while real-world studies suggest many patients ultimately require less Tresiba than their original glargine dose after proper titration. Close monitoring during the first 3-6 months is essential to optimize dosing while minimizing hypoglycemia risk.